What is HC Wainwright’s Estimate for SLN FY2030 Earnings?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for Silence Therapeutics in a research report issued to clients and investors on Friday, March 13th. HC Wainwright analyst P. Trucchio expects that the company will earn ($1.95) per share for the year. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share.

SLN has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, January 22nd. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Silence Therapeutics in a research note on Thursday, March 5th. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $34.50.

Silence Therapeutics Trading Down 1.0%

Silence Therapeutics stock opened at $6.90 on Monday. The stock has a 50 day moving average of $5.38 and a two-hundred day moving average of $5.81. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $7.83. The stock has a market capitalization of $325.89 million, a price-to-earnings ratio of -3.69 and a beta of 1.32.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.07. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.19 million. Silence Therapeutics had a negative return on equity of 101.71% and a negative net margin of 15,851.88%.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Boothbay Fund Management LLC raised its position in Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after acquiring an additional 2,409 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Silence Therapeutics by 6.6% in the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after purchasing an additional 3,935 shares during the last quarter. ADAR1 Capital Management LLC increased its stake in shares of Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Silence Therapeutics by 65.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock worth $83,000 after purchasing an additional 5,421 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Silence Therapeutics by 4.4% during the 4th quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock worth $976,000 after purchasing an additional 6,692 shares during the last quarter. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.